CAAS Capital Management’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
$1.33M Buy
+13,200
New +$1.33M 0.14% 149
2024
Q4
Sell
-2,800
Closed -$235K 398
2024
Q3
$235K Buy
2,800
+100
+4% +$7.88K 0.03% 304
2024
Q2
$208K Sell
2,700
-1,100
-29% -$80.5K 0.07% 150
2024
Q1
$260K Sell
3,800
-300
-7% -$19.3K 0.02% 381
2023
Q4
$237K Buy
+4,100
New +$219K 0.03% 340
2023
Q2
Sell
-3,200
Closed -$160K 699
2023
Q1
$160K Buy
+3,200
New +$151K 0.01% 583
2022
Q1
Sell
-60,000
Closed -$2.55M 689
2021
Q4
$2.55M Hold
60,000
0.06% 284
2021
Q3
$2.6M Hold
60,000
0.05% 310
2021
Q2
$2.57M Hold
60,000
0.04% 353
2021
Q1
$2.32M Hold
60,000
0.03% 558
2020
Q4
$2.16M Buy
+60,000
New +$2.16M 0.02% 483

Other funds holding BSX

CAAS Capital Management's BSX Position: Q1 2025 in Review

CAAS Capital Management opened a new position in Boston Scientific (BSX) in Q1 2025: 370 shares worth $37.3K. The stake represents ﹤0.01% of the portfolio and ranks #433 among its holdings. This is a return to the name: CAAS Capital Management previously reported a position in BSX as recently as Q4 2021.

CAAS Capital Management first reported a position in BSX in Q4 2020 and has held it in 6 quarters since. The position peaked at $1.64M in Q1 2021. 1,642 funds tracked by Wall St. Rank hold BSX as of Q1 2025.

  • CAAS Capital Management held 370 shares of Boston Scientific worth $37.3K as of Q1 2025.
  • Boston Scientific was a new CAAS Capital Management position in Q1 2025.
  • Boston Scientific made up ﹤0.01% of CAAS Capital Management's portfolio in Q1 2025, its #433 holding.
  • CAAS Capital Management first reported a position in Boston Scientific in Q4 2020 and has held it in 6 quarters since.
  • CAAS Capital Management's Boston Scientific position peaked at $1.64M in Q1 2021.
  • 1,642 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2025.

Based on CAAS Capital Management's 13F filing for Q1 2025, filed 1 May 2025.